A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.

Trial Details

NCT ID
NCT07459634
Phase
PHASE2
Sponsor
Jazz Pharmaceuticals
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Lurbinectedin
  • Durvalumab
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Lexington, Kentucky, United States|37.98869,-84.47772
  • Kansas City, Missouri, United States|39.09973,-94.57857

Key Eligibility Criteria

  • Participant has histologically or cytologically confirmed ES-SCLC (per Veterans Administration Lung Study Group staging system).
  • Participant has received 4 cycles of definitive platinum-based chemotherapy with at least 3 cycles of durvalumab
  • Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
  • Must have a life expectancy of ≥ 12 weeks as assessed by the treating physician.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →